Facilities

(Image: Getty/NicoElNino)

Yescarta to Europe: Steps learned and production 97% on-spec

By Ben Hargreaves

The difficulties in the manufacture of CAR-T treatments have become increasingly understood as the breakthrough technology has been commercialised, but Kite’s head of medical affairs says its process is nearly flawless.